Isoprinosine 500mg 50 tablets — Made in Hungary — Free Delivery

Pharmacodynamics. Isoprinosine is an antiviral agent with immunomodulatory properties. the preparation normalizes (to the individual norm) deficiency or dysfunction of cellular immunity, inducing the maturation and differentiation of t-lymphocytes and t1-helpers, potentiating the induction of a lymphoproliferative response in mitogenic or antigenic cells. isoprinosine simulates the cytotoxicity of T-lymphocytes and natural killer cells, the function of T8-suppressors and T4-helpers, and also increases the amount of immunoglobulin g and complement surface markers. isoprinosine increases the synthesis of interleukin (IL) -1 and IL-2, regulates the expression of IL-2 receptors. isoprinosine significantly increases the secretion of endogenous γ-interferon and reduces the production of IL-4 in the body. isoprinosine enhances the action of neutrophilic granulocytes, chemotaxis and phagocytosis of monocytes and macrophages. isoprinosine inhibits the synthesis of the virus by incorporating inosinorotic acid into the polyribosomes of the cell affected by the virus and inhibiting the attachment of adenylic acid to the viral irna.

Pharmacokinetics. After oral administration in a dose of 1.5 g, Cmax of inosine pranobex in blood plasma is reached after 1 hour and is 600 μg / ml. In the body, inosine pranobex is metabolized in the liver to form uric acid. T1 / 2 of 4- (acetylamino) benzoate is 50 minutes, 1- (dimethylamino) -2-propanol - 3.5 hours. It is excreted by the kidneys in the form of metabolites.

Viral infections caused by herpes simplex virus type 1 and 2, varicella-zoster virus, cytomegalovirus, Epstein-barr virus, measles virus, mumps virus, including in patients with immunodeficiency states; viral respiratory infections; papillomavirus infections of the skin and mucous membranes: genital warts, papillomavirus infection of the vulva, vagina and cervix (as part of complex therapy); acute viral encephalitis (as part of complex therapy); viral hepatitis (as part of complex therapy); subacute sclerosing panencephalitis (as part of complex therapy).

The preparation  is administered orally. the daily dose depends on the body weight, the course and severity of the disease, the patient's condition.

Adults and children over the age of 12 years: 50 mg / kg body weight (6-8 tablets, divided into 3-4 doses), the maximum daily dose is 4 g.

Children aged 1 to 12 years: 50 mg / kg body weight (1 tablet per 10 kg body weight for a child weighing 10–20 kg, with a body weight of 20 kg, prescribe a dose as for adults), divided into 3 –4 doses per day, the maximum daily dose is 4 g. To facilitate swallowing, the tablet can be crushed.

Acute diseases: for diseases with a short-term course of treatment is from 5 to 14 days. After a decrease in the severity of the symptoms of the disease, treatment should be continued for another 1-2 days or longer, depending on the course of the disease and the patient's condition.

Long-term viral diseases: treatment should be continued for 1–2 weeks after the severity of the symptoms of the disease or longer, depending on the course of the disease and the patient's condition.

Recurrent diseases: At the initial stage of treatment, the same recommendations apply as for acute diseases. During maintenance therapy, the dose can be reduced to 500-1000 mg (1-2 tablets) per day. When the first signs of relapse appear, it is necessary to resume taking the daily dose recommended for acute diseases, and continue using it for 1-2 days after the symptoms disappear. The course of treatment can be repeated several times if necessary and depending on the patient's condition on the recommendation of a doctor.

Chronic diseases: apply the preparation in a daily dose of 50 mg / kg body weight according to the following schemes: